Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 14/20 | 0.68 |
| ▸ | TRPA1 | O75762 | 6/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13680563 | 0.82 | TGFBR1 (0.77) | TGFBR1TRPA1MAPK14CYP2D6CYP2C9 | |
| SCHEMBL21083357 | 0.81 | TGFBR1 (1.00) | TGFBR1TRPA1MAPK14CYP2D6CYP2C9 | |
| SCHEMBL15640134 | 0.81 | TGFBR1 (0.72) | TGFBR1TRPA1MAPK14 | |
| SCHEMBL5199431 | 0.78 | TGFBR1 (0.48) | TGFBR1MAPK14CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL5492614 | 0.78 | TGFBR1 (0.58) | TGFBR1MAPK14CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL28758711 | 0.77 | TGFBR1 (0.45) | TGFBR1MAPK14 | |
| SCHEMBL30099394 | 0.77 | TGFBR1 (0.41) | TGFBR1MAPK14CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL27648484 | 0.76 | TGFBR1 (0.52) | TGFBR1MAPK14 | |
| SCHEMBL5139942 | 0.76 | TGFBR1 (0.58) | TGFBR1MAPK14 | |
| SCHEMBL29832794 | 0.76 | TGFBR1 (0.58) | TGFBR1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190292179-A1 | TGF Beta RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2019-09-26 | — | — | US | disclosed |
| US-20190292179-A1 | TGF Beta RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2019-09-26 | — | — | US | disclosed |
| WO-2018017633-A1 | TGF Beta RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292179-A1 | TGF Beta RECEPTOR ANTAGONISTS | TGFBR1, TGFBR2, TGFB1 | TGFBR1 1/4885TRPA1 1759/4885MAPK14 2427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.